approach to costing and uptake among populations considered. CONCLUSIONS: Re-to-O,T switches are a real opportunity to realise savings for budget holders and productivity gains for employers. More robust economic models are required to estimate the impact of the switches in Europe.

PHP32 MARKET ACCESS VARIATION FOR LIFESTYLE DISEASE DRUGS IN EUROPE
Bustamante AW1, Gea-Sánchez S2, Targarona M1
1EndoPharma International Limited, UK, 2City London University, London, UK
OBJECTIVES: Health policy and funding for medications classified as ‘lifestyle’ have received considerable scrutiny by public health officials as well as politicians. This has limited public funding and reimbursement for these products in many European countries. A detailed assessment of the variation in payer policy covers for lifestyle medications across Europe was conducted. METHODS: The top 1 lifestyle indications and associated medications were identified from a literature search using WHO, Pubmed, and ScienceDirect. Selection criteria for the medications included being first-to-market for being used for or being limited to the only off-label treatment for the specified use. Public reimbursement databases (16) were used to analyze the health technology assessment and reimbursement decisions across European countries (14) for each lifestyle indication. Reimbursement was classified as favourable (broad/restricted but accessible) or no coverage (not funded). Where available, justifications for coverage decisions were analysed to determine the drivers of positive and negative coverage decisions. RESULTS: Lifestyle indications where products have achieved high levels of reimbursement included Dyspepsia (100%), Delaying Menopause (91%), Restless Leg Syndrome (87%), and Alcohol Dependence (85%). Those with the least coverage were Hair Loss (0%), Hypoactive Sexual Desire Disorder (0%), Erectile Dysfunction (13%), and Weight Loss (15%). Of the 14 countries researched, those offering the most favourable coverage environments for lifestyle treatments were: Belgium (70%), France (69%), and Austria (69%). The countries with the most limited (no available) coverage for lifestyle drug therapies were The Netherlands (13%) and Sweden (25%). Four general characteristics are associated with better access to market: Cross-Usage in Other Indications, Areas with High Societal Costs, Diseases that Affect Family Planning, and Older Therapy Areas. CONCLUSIONS: With pressure on public health resources, European payers are resistant to the allocation of funds for medications with lifestyle indications. Despite this, barriers to reimbursement vary substantially across European markets.

PHP33 IMPACT OF 2011 GERMAN HEALTH CARE REFORM ON GLOBAL MARKET ACCESS STRATEGIES
Honoré AC1, Marnoni C2, Ando C2
1IHS, Zurich, Switzerland, 2IHS, London, UK
OBJECTIVES: This study seeks to evaluate the impact of the 2011 German healthcare reform (AMNOG) on the global pricing and reimbursement landscape and its influence, if any, on global market access strategies. METHODS: Key local regulators were interviewed to understand the scope and mechanism of the mandatory early benefit assessment as well as its implications in terms of pricing and market access at the national, EU and global level. Primary research was conducted through semi-structured interviews with six regulatory stakeholders and industry representatives in Germany. Secondary research was based on data from national and regional health-care authorities, national statistics offices and IHS Global Insight Healthcare and Pharmaceutical services. RESULTS: AMNOG has put an end to free pricing in Germany by correlating price to added therapeutic benefit scores and opening the reference pricing system to all patented medicines. The total transparency of the early benefit assessment and pricing processes can influence prices not only in Europe but also worldwide. The availability of a European system like the Federal Benefit Committee (G-BA)’s benefit assessment can affect the pricing and reimbursement status of pharmaceuticals worldwide, while international reference pricing can put downward pressure on prices in at least 22 other countries. CONCLUSIONS: The German reform will have an impact beyond the country’s borders. Germany has traditionally been an early pharmaceutical launch market but the end of free pricing and the prospect of lower price levels for products of no and minor-to-moderate added value may require a complete reconsideration of the optimal launch sequence. While AMNOG has revolutionized the pricing and reimbursement landscape in Germany, from a global perspective, the reform is not particularly innovative. Germany’s new pricing process is comparable to the French model whereby perceived degree of innovation directly impacts medicine prices, and comes near to the Swiss and Austrian models.

PHP34 PRICING INSIGHTS ACROSS THERAPY AREAS AND EUROPEAN COUNTRIES - A DISCUSSION OF INTERNATIONAL PRICE REFERENCES AND IMPLICATIONS FOR PARALLEL TRADE AND PRESCRIPTION PATTERN OF PHARMACEUTICAL PRODUCTS
Fonseca 1, Hasa C1, Pechstein M1, Degkas C1
1IMS HEALTH, Frankfurt/Main, Germany, 2IMS HEALTH, London, UK
OBJECTIVES: This analysis compares pricing levels across 15 European countries and 30 therapy areas in 2010. The differences in the price levels are related to parallel imports and the innovativeness of prescriptions. METHODS: From IMS PHRACING INSIGHTS pricing information for pharmaceutical products is accessed at the pack level from 15 countries (EUS-Austria-Ireland-Sweden-Norway-Denmark-Portugal-Greece-Poland-Hungary-Romania) for 2010. Currency rates are fixed at 2010 levels. Therapy areas, product classes and comparators: The therapy areas are defined as Anatomical-Therapeutic-Chemical (ATC) classes at level 2. The top 100 products by sales in the EUS in these classes enter the comparisons. Prices are compared at the manufacturer and the public sectors. IMS MIDAS identifies imports related to the products in the baskets. The innovativeness of products is measured by EUS90. More robust economic models are required to estimate the overall the first introduction and the introduction in the countries. RESULTS: The first result is that international drug price comparisons are extremely sensitive to methodological issues, e.g. sample selection, exchange rates. Differences in price build-up strategies between countries were related to parallel trade rates across countries and to an earlier access to new pharmaceutical products. CONCLUSIONS: The analysis shows price differences across countries related to manufacture pricing and regulation structuring the price build-up and taxes. Higher price levels are related to parallel trade rates across countries and to an earlier access to new pharmaceutical products. Parallel trade flows into countries with lower price levels, usually from countries with lower price levels, causing scarcities. Differences in economic development and purchasing powers need to be analysed to evaluate these differences in pricing levels.

PHP35 IS VALUE BASED PRICING EXECUTED IN REAL LIFE SITUATION? – GLOBAL PERSPECTIVES
GlaxoSmithKline, Tres Cantos, Madrid, Spain, 1Mallinson M2
OBJECTIVES: Value assessment of interventions is conducted in some form or the other, although the importance given to this step varies by market. The research is aimed to analyse how perspectives on value assessment of pharmaceuticals or device interventions vary across regions. The research also aimed to understand how aspects of factors such as development, approval, and regulatory changes were implemented. The research investigated how the perspectives and views on value assessment of new treatments were translated into price levels. The research also identified which barriers affected the perspectives and how perspectives on value assessment of pharmaceuticals or device interventions could be improved.

OBJECTIVES: The research indicated that most countries, other than those that use international reference pricing for setting prices use some form of value assessment method before fixing the reimbursement level and price of the product. The decisions are predominantly based on level of unmet needs, severity of diseases, level of innovation, clinical differentiation of the new product against its comparators and how well the product finds its natural place in the treatment pathway. Many forward regions claim to use value based assessments to set the price of new innovations, most operate within boundaries. In principal based value pricing should not be fenced with limitations such as cost/QALY thresholds, budget impact and price-volume agreements. However in real life these measures are common in markets all over the world, the main reason being the limitations in health care budgets.

CONCLUSIONS: It is very challenging to reward products based on their intrinsic value without introducing other hurdles within the current economic environment. However it also is critical to reward innovation for future investments in R&D of new drugs. Health care reforms in the future will raise the bar of innovation and differentiation making it more challenging for the Pharmaceutical industry and all those involved in developing new medicines.

PHP36 PERCEPTIONS OF POLICY MAKERS AND SCIENCE ADVICE BODY STAFF ON SCIENCE ADVICE IN HEALTH IN EUROPE
Conde Eusebio P, Palma Ruiz M, Sarria-Santamaria A, Segovia C
1Instituto de Salud Carlos III, 2Ministry of Science and Innovation, Madrid, Spain
OBJECTIVES: EurSANH is a network of science advisory bodies in Europe. The project EusAnh-ISa is funded by 7th framework programme of DG Research. It aims to improve the quality, effectiveness and efficiency of science advice for health across Europe. Within this project the objective of this work is to learn about the perceptions of policy-makers (PM) and science advise bodies’ (SAB) staff concerning the relationship between these two groups, and the current use of science advice (SA) in policy making. METHODS: Two questionnaires were designed targeting both PM involved in developing health policy (such as government ministers, officials and senior public servants within national and/or local health services) and senior staff with extensive experience working in a SAB. The questionnaire was sent to 25 PM and to 29 SAB staff. Descriptive analysis was carried out. RESULTS: Nineteen PM (3 Belgium, 1 Czech Republic, 5 Italy, 2 The Netherlands, 2 Poland, 1 Romania, 5 Spain, 3 Sweden and 1 UK) and 25 SAB staff (1 Belgium, 1 Czech Republic, 1 Italy, 1 Lithuania, 4 the The Netherlands, 1 Poland, 3 Romania, 11 Spain, and 2 from Sweden) responded the questionnaire. Factors seen as barriers for the relationship between PM and SAB were the differences in timing, interest, and difficulties to translate policy problems into research questions. The communication was seen as informal. PM and SAB considered that usefulness of SA could be improved with more clarity, brevity, simplicity and concise reporting. Transparency, independence, existence of procedures to adequately deal with conflict of interest, rigor and systematization of knowledge are factors ranked with highest value.

CONCLUSIONS: Proposals to improve the SA process are “organising regular high level meetings” and “improve the trust between decisors and researchers.”

PHP37 REGIONAL DRUG EVALUATION IN SPAIN: A COMPARISON AMONG COMMITTEES
Hernández-Pastor J1, Huerta A2
1GlaxoSmithKline, Tres Cantos, Madrid, Spain, 2GlaxoSmithKline, Tres Cantos, Madrid, Spain

Value in Health 14 (2011) A239-A510

A339